BLZ945

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Advanced Solid TumorsAmyotrophic Lateral Sclerosis

Phase 1

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

TerminatedNCT02829723

Novartis PharmaceuticalsAdvanced Solid Tumors

Start: 2016-10-21End: 2022-12-01Updated: 2024-01-18

Phase 2

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

TerminatedNCT04066244

Novartis PharmaceuticalsAmyotrophic Lateral Sclerosis

Start: 2019-12-30End: 2024-02-01Updated: 2025-10-16

Related Papers

Abstract CT094: Targeting CSF1R with BLZ945 results in effective peripheral and tumor immune microenvironment modulation in advanced solid tumors and may be associated with limited efficacy in recurrent non-mesenchymal glioblastoma

Cancer Research2024-04-054 citations

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

Abstract CT171: Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors

Cancer Research2020-08-1533 citations

Abstract CT172: Pharmacodynamic and gene expression profiling of patients treated with BLZ945 + spartalizumab demonstrates on-target peripheral and tumor immune microenvironment modulation

Cancer Research2020-08-152 citations